Status:
COMPLETED
The Malmö International Brother Study (MIBS)
Lead Sponsor:
Skane University Hospital
Conditions:
Hemophilia A With Inhibitors
Eligibility:
MALE
Brief Summary
Existing data support the concept that a genetic predisposition for inhibitor development exists. The aim of the Malmö International Brother Study (MIBS) is to evaluate genetic factors associated with...
Detailed Description
Inhibitory antibodies to factor VIII develop in 10-15% of all patients with hemophilia A and in 25-30% of patients with the severe form of the disease after exposure to factor VIII concentrates. Both ...
Eligibility Criteria
Inclusion
- Mild, moderate or severe hemophilia A or B and one or more brothers with mild, moderate or severe hemophilia A or B
Exclusion
- Absence of sufficient information to classify inhibitor status
Key Trial Info
Start Date :
November 1 2002
Trial Type :
OBSERVATIONAL
End Date :
June 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00231751
Start Date
November 1 2002
End Date
June 1 2004
Last Update
October 4 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Malmö University Hospital
Malmo, Sweden